REMS For Individual Opioids Show FDA Flexibility, Keep Class Options Open

As FDA works with stakeholders on a class-wide Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, the REMS that have been approved for individual opioid products indicate agency flexibility in addressing risk management, according to Edgar Adams, executive director of epidemiology at Covance